CTOs on the Move

Dicerna

www.dicerna.com

 
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dicerna.com
  • 33 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.621.8097

Executives

Name Title Contact Details

Funding

Dicerna raised $70M on 03/30/2017
Dicerna raised $100M on 10/29/2018

Similar Companies

TTG Imaging Solutions

Your partner for nuclear medicine and molecular imaging solutions.

Nucryst Pharmaceuticals

Nucryst Pharmaceuticals Corp. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

Proneuron Biotechnologies

Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MOLLI Surgical

#Healthcare needs to get simpler to get better. To achieve this, we focus on the #patientexperience and develop more effective #medicaldevices. #breastcancer